China’s rapid advancements in artificial intelligence have drawn significant global attention, but a quieter, yet equally transformative shift is occurring in its biotech sector. Moving beyond its traditional role as a producer of generic medicine, raw ingredients, and a hub for clinical trials, China is emerging as a global leader in medicine innovation, challenging the established dominance of Western pharmaceutical companies. This transformation is driven by a strategic convergence of government policy, increased R&D investment, and a maturing biotech ecosystem.

For years, China’s pharmaceutical industry focused on producing affordable generics and serving as a global manufacturing base. This experience allowed the country to build a strong foundation of expertise and infrastructure. However, recognizing the growing global demand for innovative treatments and anticipating the expiration of numerous medicine patents, Chinese pharmaceutical companies have strategically shifted towards developing novel medicine. One notable example of China's growing prowess in biotech innovation is Akeso Therapeutics, whose groundbreaking medicine, Ivonescimab, has attracted international attention. This PD-1/VEGF bispecific antibody has shown remarkable promise in clinical trials, outperforming Keytruda, a leading immunotherapy treatment, in the treatment of non-small cell lung cancer. The success of Ivonescimab has led to significant licensing agreements with Western firms, highlights China's increasing capabilities in developing innovative therapies. This shift is not merely a reaction to market forces, but a deliberate, government-backed initiative supported by significant financial incentives, tax breaks, and subsidies aimed at fostering innovation. Chinese biotech firms have applied advancements in artificial intelligence and big data to accelerate medicine discovery and development, enabling researchers to analyze complex biological data, identify potential medicine targets, and optimize clinical trials with unprecedented speed and efficiency.

A key factor in China's success in biotech industry is its ability to produce innovative medicines at lower costs than competitors. This advantage stems from lower labor costs, streamlined regulatory processes, and the effective integration of AI into the medicine development pipeline. By offering cutting-edge therapies at competitive prices, Chinese medicine makers are securing a larger share of the domestic market and gaining increasing recognition internationally.  The impact of this strategic shift is already evident. China has become the second-largest developer of new medicines globally, trailing only the United States. Facing potential revenue losses due to expiring patents, Western pharmaceutical companies are increasingly turning to Chinese firms for innovative solutions, forging licensing agreements and collaborations at an unprecedented rate. Data reveals a significant increase in licensing deals between Western and Chinese firms, highlighting the growing recognition of China's innovative capabilities.

Crucial to China's biotech strategy is a renewed emphasis on intellectual property (IP) protection. Recognizing past weaknesses in IP protection that hindered foreign investment and collaboration, China has implemented significant reforms: Strengthening its IP laws and aligning them more closely with international standards. These reforms have fostered greater confidence among global partners and encouraged Chinese firms to invest heavily in original research, leading to a surge in patent filings for novel therapies. This focus on IP not only strengthens China's competitive edge but also positions its companies as attractive partners for Western firms seeking access to cutting-edge medicine development.

Despite the remarkable progress made by China's biotech sector, several challenges remain that could potentially impede future growth. Regulatory hurdles, talent acquisition difficulties, and ongoing geopolitical tensions pose significant obstacles. Furthermore, Chinese firms face the complex task of scaling their innovations globally, which includes navigating the stringent regulatory requirements of Western markets. Nevertheless, the overall trajectory is clear: China's biotech sector is poised to play an increasingly influential role in global medicine development, driven by the country's strategic focus on scientific research, cost-effectiveness, and intellectual property protection. This transformation from a primarily generic medicine manufacturer to a global hub of pharmaceutical innovation benefits the Chinese economy and holds immense promise for making life-saving treatments more accessible worldwide.

However, potential headwinds, such as protectionist policies and trade tensions, particularly from the U.S., may seek to curb this trend through measures like stricter regulations on licensing deals or heightened scrutiny of Chinese biopharma investments. Yet, such measures risk limiting access to innovative, cost-effective treatments developed through global collaboration, ultimately undermining the shared goal of improving global healthcare outcomes. 

By Dr. Bankee Kwan

Member of the Chinese People’s Political Consultative Conference National Committee and President of the Federation of Hong Kong-Shanghai Associations.

Dr. Philip Wong

Deputy Director of STEAM Education and Research Centre, Lingnan University.

The views do not necessarily reflect those of Orange News.

File Photo